A Phase 1 Study of ARRY-614 in Patients with Low or Intermediate-1 RiskMyelodysplastic Syndromes

Trial Profile

A Phase 1 Study of ARRY-614 in Patients with Low or Intermediate-1 RiskMyelodysplastic Syndromes

Completed
Phase of Trial: Phase I

Latest Information Update: 02 Jan 2015

At a glance

  • Drugs Pexmetinib (Primary)
  • Indications Myelodysplastic syndromes
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Array BioPharma
  • Most Recent Events

    • 29 Dec 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 10 Dec 2013 Interim results presented at the 55th Annual Meeting and Exposition of the American Society of Hematology.
    • 09 Dec 2013 Mature data from this trial are expected in 2014, according to an Array BioPharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top